Regeneron Pharmaceuticals, Inc. (REGN) fair value analysis

S&P 500 · Updated 2026-09-07

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious medical conditions in areas including oncology, immunology, cardiovascular disease, and ophthalmology. The company operates globally with research, manufacturing, and commercial operations across the United States and international markets.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, REGN is trading at within about 10% of estimated fair value.

REGN currently ranks #71 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $827.72
Sector: Healthcare
12-month range: $600.66–$823.82

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for REGN

Our model validated 17 trailing price-to-earnings windows for REGN, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $600.66–$823.82.
The 14-day relative strength index sits at a neutral 60.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for REGN
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent REGN news

TickrTrends' derived news-sentiment signal for REGN is currently mixed, computed from recent coverage.

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (markets.businessinsider.com, 2026-09-05)
TickrTrends take: Regeneron Pharmaceuticals trades at a Fairly valued assessment according to TickrTrends, meaning current market pricing reflects reasonably aligned fundamental metrics for this Healthcare sector company. The announcement of an investor deadline for a class action lawsuit introduces legal risk that valuation models may not fully capture, particularly if material settlements or judgments emerge. Investors monitoring REGN's valuation should track how legal proceedings develop, as significant litigation outcomes could reshape the company's financial position and warrant reassessment of its current fair value standing.
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle? (insidermonkey.com, 2026-08-27)
TickrTrends take: Regeneron operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends, suggesting the market has already priced in much of the company's current prospects. A valuation-focused reader should monitor whether the company's rare-disease successes can translate into earnings growth that either justifies the current valuation or creates upside potential. The key question for investors tracking REGN's valuation is whether these clinical wins represent sustainable competitive advantages or represent consensus expectations already embedded in the stock's price.
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials (finance.yahoo.com, 2026-08-27)
TickrTrends take: Regeneron Pharmaceuticals operates in the Healthcare sector where clinical trial outcomes directly impact pipeline value and future revenue potential, making them a key metric for valuation assessments. The mixed results in melanoma drug trials introduce uncertainty around expected cash flows from this program, which TickrTrends currently reflects in its Fairly valued assessment. Investors focused on valuation should monitor whether this trial setback leads to pipeline revisions or shifts in revenue guidance that could alter the current fair value positioning.

What people are saying

Follow the REGN conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — REGN's momentum indicator declined this week, shifting from a positive rating to no indicator reading. The stock maintains a fairly valued assessment based on current valuation metrics. This change in momentum tracking may reflect reduced directional strength in the stock's recent price movement.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is REGN stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), REGN is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is REGN's TickrTrends verdict?

REGN's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does REGN compare to other Healthcare stocks?

REGN ranks #71 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is REGN overbought or oversold?

REGN's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

REGN vs AZTA · REGN vs BAX · REGN vs COR · REGN vs ELV · REGN vs HSIC